{"id":"treatment-with-brimonidine-timolol","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular hyperemia"},{"rate":null,"effect":"Eye irritation"},{"rate":null,"effect":"Dry eye"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Allergic conjunctivitis"}]},"_chembl":{"chemblId":"CHEMBL2062257","moleculeType":"Small molecule","molecularWeight":"442.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Brimonidine stimulates alpha-2 adrenergic receptors to decrease aqueous humor production and increase uveoscleral outflow. Timolol blocks beta-adrenergic receptors to reduce aqueous humor production. The combination provides additive intraocular pressure-lowering effects with complementary mechanisms of action.","oneSentence":"Brimonidine is an alpha-2 adrenergic agonist and timolol is a non-selective beta-blocker; together they reduce intraocular pressure through different pathways to treat glaucoma.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:14:10.612Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT07074782","phase":"","title":"Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues","status":"NOT_YET_RECRUITING","sponsor":"Association for Innovation and Biomedical Research on Light and Image","startDate":"2026-01","conditions":"Glaucoma","enrollment":1500},{"nctId":"NCT03193333","phase":"PHASE3","title":"PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2017-11-06","conditions":"Primary Open-angle Glaucoma","enrollment":51},{"nctId":"NCT06761313","phase":"PHASE4","title":"Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Federal University of São Paulo","startDate":"2021-03-01","conditions":"Glaucoma, Quality of Life (QOL)","enrollment":40},{"nctId":"NCT03220490","phase":"NA","title":"Efficacy and Necessity of Time Interval Between Instillation of Two Glaucoma Eye Drops","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2017-11-01","conditions":"Glaucoma, Glaucoma; Drugs","enrollment":65},{"nctId":"NCT00981786","phase":"PHASE4","title":"24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2009-08","conditions":"Glaucoma","enrollment":51},{"nctId":"NCT03966365","phase":"PHASE1","title":"Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno®","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2019-05-02","conditions":"Glaucoma","enrollment":24},{"nctId":"NCT03257813","phase":"PHASE3","title":"Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2016-04-01","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":60},{"nctId":"NCT01062971","phase":"PHASE2","title":"Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2006-02","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":124},{"nctId":"NCT03966560","phase":"PHASE4","title":"Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Afyon Kocatepe University Hospital","startDate":"2014-01","conditions":"Glaucoma, Open-Angle","enrollment":96},{"nctId":"NCT02730871","phase":"PHASE4","title":"Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2016-06-24","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":173},{"nctId":"NCT01170884","phase":"PHASE4","title":"Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-12","conditions":"Glaucoma, Ocular Hypertension","enrollment":121},{"nctId":"NCT02167035","phase":"PHASE4","title":"Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)","status":"COMPLETED","sponsor":"Cornerstone Health Care, PA","startDate":"2014-08","conditions":"Glaucoma, Ocular Hypertension","enrollment":43},{"nctId":"NCT01217606","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-01","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":185},{"nctId":"NCT02214680","phase":"PHASE2","title":"The Effect of Topical Treatment With Combigan Compared to Timolol and Brimonidine on Pupil Diameter","status":"UNKNOWN","sponsor":"Carmel Medical Center","startDate":"2015-10","conditions":"Healthy","enrollment":25},{"nctId":"NCT01978600","phase":"PHASE4","title":"Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-10","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":89},{"nctId":"NCT00275756","phase":"NA","title":"Effects of Common Topical Glaucoma Therapy on Optic Nerve Head Blood Flow Autoregulation During Increased Arterial Blood Pressure and Artificially Elevated Intraocular Pressure in Healthy Humans","status":"WITHDRAWN","sponsor":"Medical University of Vienna","startDate":"2008-09","conditions":"Glaucoma","enrollment":""},{"nctId":"NCT01241240","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-03","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":192},{"nctId":"NCT00972257","phase":"PHASE4","title":"24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2009-01","conditions":"Glaucoma","enrollment":64},{"nctId":"NCT01987752","phase":"","title":"Safety and Efficacy of Combigan® Ophthalmic Solution in Korea","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-01","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":732},{"nctId":"NCT01216943","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-11","conditions":"Glaucoma, Ocular Hypertension","enrollment":126},{"nctId":"NCT01284166","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"WITHDRAWN","sponsor":"Allergan","startDate":"2013-07","conditions":"Glaucoma, Ocular Hypertension","enrollment":""},{"nctId":"NCT01887223","phase":"PHASE2","title":"Transconjunctival Needling Revision Versus Medical Treatment","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2010-05","conditions":"Primary Open Angle Glaucoma","enrollment":40},{"nctId":"NCT00800540","phase":"PHASE4","title":"Circadian Ocular Perfusion Pressure and Ocular Blood Flow","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-02","conditions":"Glaucoma","enrollment":35},{"nctId":"NCT01255306","phase":"","title":"The Influence of Silicone Oil on Nerve Fiber Layer Thickness After Pars Plana Vitrectomy","status":"COMPLETED","sponsor":"University Hospital Sestre Milosrdnice","startDate":"2010-04","conditions":"Rhegmatogenous Retinal Detachment, Toxic Effect of Silicone, Glaucoma Due to Silicon Oil","enrollment":60},{"nctId":"NCT01004900","phase":"PHASE3","title":"Intraocular Pressure (IOP) Lowering Effect of Selective Laser Trabeculoplasty Versus Prostaglandin Analogues in Angle Closure Glaucoma","status":"UNKNOWN","sponsor":"Singapore Eye Research Institute","startDate":"2009-06","conditions":"Glaucoma","enrollment":90},{"nctId":"NCT00822055","phase":"PHASE4","title":"Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2005-05","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":140},{"nctId":"NCT00822081","phase":"PHASE4","title":"Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2005-01","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":140},{"nctId":"NCT00698945","phase":"PHASE4","title":"Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2008-06","conditions":"Ocular Hypertension, Open-Angle Glaucoma","enrollment":40},{"nctId":"NCT00652106","phase":"PHASE3","title":"Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2003-06","conditions":"Glaucoma, Ocular Hypertension","enrollment":432},{"nctId":"NCT00317577","phase":"PHASE2","title":"Study of Medical Treatment of Low-Pressure (Normal Tension) Glaucoma","status":"COMPLETED","sponsor":"Chicago Center for Vision Research","startDate":"1998-12","conditions":"Glaucoma, Open Angle","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":86,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"treatment with brimonidine/timolol","genericName":"treatment with brimonidine/timolol","companyName":"Aristotle University Of Thessaloniki","companyId":"aristotle-university-of-thessaloniki","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Brimonidine is an alpha-2 adrenergic agonist and timolol is a non-selective beta-blocker; together they reduce intraocular pressure through different pathways to treat glaucoma. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}